Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Letrozole and Misoprostol for Early Pregnancy Loss Management
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 30
- Registration Number
- NCT06452719
- Locations
- 🇺🇸
PEACE / Penn Medicine, Philadelphia, Pennsylvania, United States
Sequential Letrozole and Methotrexate Therapy Role in Treatment of Tubal Ectopic Pregnancy
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 200
- Registration Number
- NCT06426979
- Locations
- 🇪🇬
Zagazig university, Zagazig, Ash Sharqia Governorate, Egypt
Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 150
- Registration Number
- NCT06418347
- Locations
- 🇪🇬
Ain shams university, Cairo, Egypt
Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 500
- Registration Number
- NCT06405178
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Egypt
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06394804
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06380751
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 76
- Registration Number
- NCT06366347
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Breast Cancer & Antiestrogenic Therapy & Brain
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- International Research Training Group 2804
- Target Recruit Count
- 180
- Registration Number
- NCT06346457
- Locations
- 🇩🇪
University of Tuebingen; Department of Psychiatry & Psychotherapy Tuebingen, Tuebingen, BW, Germany
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 74
- Registration Number
- NCT06348134
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 78
- Registration Number
- NCT06253195
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.